Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials

CpG 7909 in Treating Patients Who Have Undergone Autologous Stem Cell Transplant

This study has been terminated.
(Slow accrual)
Sponsor:
Information provided by (Responsible Party):
Masonic Cancer Center, University of Minnesota
ClinicalTrials.gov Identifier:
NCT00369291
First received: August 24, 2006
Last updated: November 6, 2012
Last verified: November 2012

August 24, 2006
November 6, 2012
September 2003
May 2010   (final data collection date for primary outcome measure)
Enhanced immune function as measured by response to keyhole limpet hemocyanin and tetanus toxoid [ Time Frame: 1 Month after vaccine ] [ Designated as safety issue: No ]
anti-KLH IgG
Not Provided
Complete list of historical versions of study NCT00369291 on ClinicalTrials.gov Archive Site
Impact of dose escalation of CpG 7909 on primary immune readouts [ Time Frame: At study completion ] [ Designated as safety issue: No ]
Compare primary outcome between cohorts
Not Provided
Not Provided
Not Provided
 
CpG 7909 in Treating Patients Who Have Undergone Autologous Stem Cell Transplant
CPG 7909 Oligodeoxynucleotides (ODNS) After Autologous Transplantation to Enhance Immune Reconstitution

RATIONALE: Giving CpG 7909 after an autologous stem cell transplant may make a stronger immune response and prevent or delay the recurrence of cancer.

PURPOSE: This phase I trial is studying the side effects and best dose of CpG 7909 in treating patients who have undergone autologous stem cell transplant.

OBJECTIVES:

Primary

  • Determine whether CpG 7909 enhances immune function, as measured by the response to keyhole limpet hemocyanin (neo-antigen) and tetanus toxoid (memory antigen), in patients who have undergone autologous stem cell transplantation.

Secondary

  • Determine if dose escalation of CpG 7909, within a range of previously tested safe doses of CpG 7909, impacts upon the primary immune readouts.

OUTLINE: This is a non-randomized, dose-escalation study of CpG 7909.

Patients receive CpG 7909 subcutaneously (SC) on days 1, 7, and 14. Patients receive keyhole limpet hemocyanin SC and tetanus toxoid SC on day 7.

Cohorts of 3-6 patients receive escalating doses of Cp6 7909 until the maximum tolerated dose (MTD) is determined. The MTD is defined as the dose preceding that at which 2 of 3 or 2 of 6 patients experience dose-limiting toxicity. A total of 10 patients are treated at the MTD.

Blood is collected at baseline and at approximately day 40 for immunological studies, including immunoenzyme techniques, antibody response assays, and immunophenotyping.

After completion of study treatment, patients are followed every 3 months for 1 year.

Interventional
Phase 1
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment
  • Germ Cell Tumor
  • Leukemia
  • Lymphoma
  • Multiple Myeloma and Plasma Cell Neoplasm
  • Biological: keyhole limpet hemocyanin
    KLH is a foreign protein to humans, it will be used to assess the immune response to a neo-antigen given as a single injection, 1 mg subcutaneously in the arm (per MT1999-06).
    Other Name: KLH
  • Biological: tetanus toxoid
    Tetanus toxoid booster 0.5 ml intramuscularly (IM) in the opposite arm (per MT1999-06)
Experimental: CpG 7909
Patients treated with CpG 7909 oligodeoxynucleotides (ODNs) after autologous transplantation to enhance immune reconstitution.
Interventions:
  • Biological: keyhole limpet hemocyanin
  • Biological: tetanus toxoid
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Terminated
19
May 2010
May 2010   (final data collection date for primary outcome measure)

Inclusion Criteria:

  • Patients must have undergone autologous transplantation for non-Hodgkin's lymphoma (NHL), Hodgkin's disease, acute myelogenous leukemia (AML), germ cell tumors, or multiple myeloma.
  • Patients must be eligible for and consent to participate in study MT1999 06 - Vaccination with tetanus toxoid and Keyhole Limpet Hemocyanin (KLH) to assess antigen specific immune responses (BB-IND 10430).
  • Patients will be eligible to receive CpG 7909 and vaccines on or after day 60 post transplant. No patients are eligible for this protocol beyond day 74 post transplant. Therefore, all patients will start therapy on this protocol between days 60-74 post transplant to allow for patient scheduling flexibility.
  • Patients must have engraftment and be independent of transfusion support or growth factor support.
  • Patients must not have received platelet or red-cell transfusions in the previous week.
  • Patients must have been continuously off all growth factors for at least 1 week.
  • Unsupported counts must be:

    • platelets ≥ 50,000/ml
    • Hgb ≥ 9 gm/ul
    • Absolute neutrophil count ≥ 1000/µL
    • Absolute lymphocyte count ≥ 500/µL
  • Patients must have a current performance status of 0-1 (Eastern Cooperative Oncology Group) or 70-100% (Karnofsky.
  • Patients must be afebrile, off antibiotics therapeutic (not prophylactic), and free of evidence of active infection. Patients must be off intravenous (IV) hyperalimentation and IV fluids.
  • Minimum laboratory values within 2 weeks of entry: Creatinine ≤ 2.0 mg/dl or CrCl ≥ 50 ml/min, Bilirubin, ALT ≤ 2 x normal
  • Age >18 years
  • Patients receiving or scheduled to receive planned radiation therapy, growth factor therapy, or steroid therapy during the study period will be ineligible. Patients must have completed all planned post-transplant radiation therapy if applicable.
  • Patients must be able to give written informed consent and agree to comply with the study parameters
  • Patients must agree to use contraception during the study.

Exclusion Criteria:

Patients with one or more of the following:

  • Active infection, or fever >38.2˚C
  • Significant nonmalignant disease including documented HIV infection, uncontrolled hypertension (diastolic blood presses >115 mmHg), unstable angina, congestive heart failure (NY Class II), poorly controlled diabetes, coronary angioplasty within 6 months, myocardial infarction with the last 6 months, or uncontrolled atrial or ventricular cardiac arrhythmias.
  • Hematopoietic growth factors administered within 1 week of study entry.
  • Expected to require additional cytotoxic therapy within 30 days of study
  • Receiving other post-transplant investigational agents
  • Patients with a history of autoimmune diseases will be ineligible for this protocol
  • It is unknown whether CpG 7909 may exacerbate autoimmune disorders by its immunomodulatory effects. Therefore, subjects with a history of autoimmune disease should not receive CpG 7909. Controlled thyroid disease is permissible.
  • Systemic corticosteroids or other immunosuppressants
  • Pregnant or lactating (It is unlikely and probably unwise that a women of childbearing potential become pregnant this early after transplant, however; if any suspicion, a pregnancy test should be done)
  • Not meeting one or more of the eligibility criteria, as listed above
Both
18 Years and older
No
Contact information is only displayed when the study is recruiting subjects
United States
 
NCT00369291
2003LS014, UMN-0302M41542, UMN-MT2003-03
Yes
Masonic Cancer Center, University of Minnesota
Masonic Cancer Center, University of Minnesota
Not Provided
Principal Investigator: Marcie Tomblyn, MD, MS Masonic Cancer Center, University of Minnesota
Masonic Cancer Center, University of Minnesota
November 2012

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP